Short Interest in OPKO Health, Inc. (NASDAQ:OPK) Decreases By 14.0%

OPKO Health, Inc. (NASDAQ:OPK) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 84,800,000 shares, a decline of 14.0% from the November 30th total of 98,570,000 shares. Approximately 27.4% of the shares of the company are short sold. Based on an average trading volume of 3,950,000 shares, the short-interest ratio is presently 21.5 days.

OPKO Health Stock Down 2.6 %

Shares of OPK opened at $1.48 on Monday. The company has a market capitalization of $1.01 billion, a P/E ratio of -7.79 and a beta of 1.62. OPKO Health has a one year low of $0.85 and a one year high of $1.76. The business’s 50 day simple moving average is $1.55 and its 200-day simple moving average is $1.48. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69.

Insider Buying and Selling at OPKO Health

In related news, CEO Phillip Md Et Al Frost acquired 280,183 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were acquired at an average price of $1.50 per share, for a total transaction of $420,274.50. Following the completion of the purchase, the chief executive officer now directly owns 211,512,405 shares of the company’s stock, valued at $317,268,607.50. The trade was a 0.13 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders purchased a total of 1,304,255 shares of company stock worth $2,024,605 over the last ninety days. Company insiders own 47.26% of the company’s stock.

Hedge Funds Weigh In On OPKO Health

A number of large investors have recently modified their holdings of the stock. World Investment Advisors LLC bought a new position in OPKO Health in the third quarter valued at about $61,000. Virtu Financial LLC acquired a new position in OPKO Health during the 3rd quarter valued at about $120,000. Barclays PLC boosted its stake in shares of OPKO Health by 154.5% in the 3rd quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock valued at $810,000 after purchasing an additional 329,870 shares during the last quarter. Orion Portfolio Solutions LLC acquired a new stake in shares of OPKO Health during the 3rd quarter worth approximately $45,000. Finally, XTX Topco Ltd raised its stake in shares of OPKO Health by 166.5% during the third quarter. XTX Topco Ltd now owns 108,652 shares of the biotechnology company’s stock worth $162,000 after buying an additional 67,883 shares during the last quarter. 64.63% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

OPK has been the subject of a number of analyst reports. StockNews.com lowered shares of OPKO Health from a “hold” rating to a “sell” rating in a research note on Thursday. Piper Sandler reiterated an “overweight” rating and set a $3.00 price target on shares of OPKO Health in a report on Tuesday, September 17th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a research note on Thursday, September 26th. Finally, Barrington Research reissued an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a research report on Friday, November 8th.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.